Inclusion Criteria:

- Histologically or cytologically confirmed small cell lung cancer

- No mixed histology

- Extensive stage disease, defined as any of the following:

- Metastatic disease outside the chest

- Contralateral supraclavicular nodes or contralateral hilar nodes that cannot be
included in a single radiation port

- Cytologically confirmed malignant pleural effusion

- Clinically significant effusions (e.g., symptomatic pleural effusion) must
be drained prior to treatment

- Previously untreated disease* OR stable disease, partial response, or complete
response ≤ 4 weeks after completion of one course (four 3-week courses) of standard
platinum-based chemotherapy

- No symptomatic, untreated, or uncontrolled CNS metastases

- CNS metastases previously treated with whole brain radiotherapy allowed

- ECOG performance status (PS) 0-2

- Life expectancy ≥ 12 weeks

- WBC ≥ 3,000/mm³

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin > 9.0 g/dL

- Total bilirubin < 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 3 times ULN

- ALT and AST ≤ 3 times ULN (≤ 5 times ULN if liver involvement)

- Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min

- Proteinuria ≤ +1 on two consecutive dipsticks taken no less than 24hours apart

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective protection during and for up to 8 weeks after
completion of study therapy

- QTc interval ≤ 460 msec

- No seizure disorder

- No significant traumatic injury ≤ 4 weeks prior to registration

- No clinically significant infection

- No HIV-positivity

- No second primary malignancy, except for carcinoma in situ of the cervix or
nonmelanoma skin cancer, unless prior malignancy was diagnosed and treated ≥ 5 years
with no subsequent evidence of recurrence

- Patients with a history of low grade(Gleason score ≤ 6) localized prostate
cancer will be eligible even if diagnosed < 5 years prior to registration

- No concurrent severe and/or uncontrolled medical conditions, including any of the
following:

- Cardiac arrhythmias

- Angina pectoris uncontrolled with medication

- Myocardial infarction within the past 3 months

- Significant ECG abnormalities

- Hypertension, labile hypertension, or history of poor compliance with
anti-hypertensive medication

- Congestive heart failure within the past 3 months, unless ejection fraction >
40%

- Interstitial pneumonia or extensive, symptomatic interstitial fibrosis of the
lung

- Poorly controlled diabetes

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to AZD0530

- No condition that impairs the ability to swallow AZD0530 tablets, including any of
the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication
or requiring IV alimentation

- Prior surgical procedures affecting absorption of AZD0530 tablets

- Active peptic ulcer disease

- No serious condition that, in the opinion of the investigator, would compromise the
patient's ability to complete the study

- At least 4 weeks since prior major surgery (i.e., laparotomy) or open biopsy

- At least 2 weeks since prior minor surgery

- At least 4 weeks since any prior investigational ancillary therapy (i.e., utilized
for a non-FDA-approved indication and in the context of a researchinvestigation)

- At least 7 days since prior use of strong inhibitors of CYP3A4 and no concurrent use
for up to 7 days after discontinuation of AZD0530

- Prior nonthoracic palliative radiotherapy allowed

- Concurrent bisphosphonates for treatment of lytic metastatic bone disease allowed at
the discretion of the treating physician

- No concurrent prophylactic granulocyte colony-stimulating factor (i.e., G-CSF)

- No concurrent products that stimulate thrombopoiesis

- No concurrent St. John's wort

- No other concurrent chemotherapy, immunotherapy, hormonal therapy,or radiotherapy